Some information is hidden away in supplemental table 6, which points out candidate drugs to affect different biological pathways for different mutations.
would provide information on treatment decisions generally made by finding appropriate subtype classifications.
I think that it is pretty clear that genomic sequencing of patient normal and tumor tissue to find mutations is going to be standard-of-care sooner rather than later, but it is fair to point out that genomic sequencing is not currently standard-of-care. However, I know of studies currently underway that look at variant calls and the possibility of taking action on those calls in ways the involve specifically adding those results back into the patient medical record.
I am struggling a bit with how to phrase this, but I don't think you can argue against (1) different subtypes of breast cancer are separate diseases and can be classified by genomic sequencing and (2) treatments for these separate diseases are different and have different efficacies.
You could also skim
http://www.nature.com/nature/journal/v406/n6797/full/406747a...
for more information about genomic classification of breast cancer.
From a treatment prespective, I would say that just glancing at http://ww5.komen.org/BreastCancer/SubtypesofBreastCancer.htm...
would provide information on treatment decisions generally made by finding appropriate subtype classifications.
I think that it is pretty clear that genomic sequencing of patient normal and tumor tissue to find mutations is going to be standard-of-care sooner rather than later, but it is fair to point out that genomic sequencing is not currently standard-of-care. However, I know of studies currently underway that look at variant calls and the possibility of taking action on those calls in ways the involve specifically adding those results back into the patient medical record.
I am struggling a bit with how to phrase this, but I don't think you can argue against (1) different subtypes of breast cancer are separate diseases and can be classified by genomic sequencing and (2) treatments for these separate diseases are different and have different efficacies.